Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi,Jacob D Soumerai,Kathleen A Dorritie,Deborah M Stephens,Peter A Riedell,Jon E Arnason,Thomas J Kipps,Heidi H Gillenwater,Lucy Gong,Jason A Dubovsky,Julie Rytlewski,Lin Yang,William G Wierda

doi:10.1182/blood-2019-127603

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, Jacob D Soumerai + Show 11 more

Open Access

https://doi.org/10.1182/blood-2019-127603

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 24

Affiliation: City Of Hope National Medical Center, Massachusetts General Hospital, UPMC Hillman Cancer Center, Huntsman Cancer Institute, University of Chicago Medical Center, Beth Israel Deaconess Medical Center, University of California, San Diego, The University of Texas MD Anderson Cancer Center

#Research Funding #Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Full Text